Digest Network Come funziona
Network
/
Società
La
Non verificato

Lantern Pharma Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaOncologiaSaluteTecnica

39 comunicati stampa

Guarda tutti i comunicati
03/12/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Medicina - Varie
Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into Multiple Biomarker-Guided Phase 1b/2 Trials
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Tecnica
Igiene alimentare
Sanità
Salute
Farmaceutica
Oncologia
Scienza
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
06/11/2025
Tecnica
Software
Biotecnologia
Salute
Farmaceutica
Information Technology
Oncologia
Web e Social Network
Telefonia e Varie
Finanza
Lantern Pharma to Report Third Quarter 2025 Operating & Financial Results on November 13th, 2025 at 9:00 a.m. ET
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Eventi
Industria
Scienza
Tecnica
Software
Biotecnologia
Farmaceutica
Salute
Oncologia
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
28/10/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Tecnica
Lantern Pharma Presents LP-284 Clinical Data at 25th LL&M Congress, Highlighting Complete Response in Therapeutically Exhausted DLBCL Patient & Therapeutic Potential in Advanced B-Cell Cancers.
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
24/10/2025
Eventi
Web e Social Network
Sanità
Software
Farmaceutica
Oncologia
Information Technology
Tecnica
Medicina - Varie
Biotecnologia
Salute
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2025
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
16/09/2025
Biotecnologia
Farmaceutica
Oncologia
Salute
Tecnica
Medicina - Varie
Industria
Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
03/09/2025
Scienza
Farmaceutica
Oncologia
Vetrine/Shopping
Infanzia
Medicina - Varie
Biotecnologia
Igiene alimentare
Salute
Industria
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
13/08/2025
Tecnica
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Oncologia
Scienza
Reti informatiche
Information Technology
Medicina - Varie
Mercato azionario
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0
06/08/2025
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Tecnica
Medicina - Varie
Industria
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
Fonte
Lantern Pharma Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0